With a successful music career already in the bag, 24-year-old Fredrik Guzmán Lindemark is now making his mark as a start-up entrepreneur and investor.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh